Compounds > gemcitabine
Page last updated: 2024-08-24

gemcitabine and rosiglitazone

gemcitabine has been researched along with rosiglitazone in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Chen, J; Feng, YH; Gully, C; Lee, MH; Velazquez-Torres, G; Yeung, SC1
Koga, H; Sata, M; Selvendiran, K; Sivakumar, R; Torimura, T; Ueno, T; Yoshida, T1
Bailey, JM; Bunt, SK; Grandgenett, PM; Hollingsworth, MA; Mohr, AM1

Reviews

1 review(s) available for gemcitabine and rosiglitazone

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for gemcitabine and rosiglitazone

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.
    Journal of cellular and molecular medicine, 2011, Volume: 15, Issue:4

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms; Pancreatic Neoplasms; Rosiglitazone; Thiazolidinediones

2011
PPARĪ³ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.
    International journal of oncology, 2012, Volume: 40, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; fas Receptor; Gemcitabine; Histone Deacetylases; Humans; Ligands; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Pioglitazone; PPAR gamma; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand; Rosiglitazone; Thiazolidinediones; Valproic Acid; Xenograft Model Antitumor Assays

2012
Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.
    Cancer immunology, immunotherapy : CII, 2013, Volume: 62, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Immunosuppression Therapy; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Pioglitazone; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Xenograft Model Antitumor Assays

2013